Cynata Therapeutics Ltd represents values of innovation, collaboration, and dedication. With a strong corporate philosophy focused on developing novel stem cell therapies, Cynata is committed to improving patient outcomes and addressing unmet medical needs. As a leading biotechnology company, Cynata operates with a passion for scientific excellence and a drive to deliver transformative treatments. By harnessing the unique capabilities of its proprietary Cymerus™ technology, the company aims to revolutionize the field of regenerative medicine. Cynata Therapeutics Ltd prioritizes ethical practices, community engagement, and the pursuit of groundbreaking advancements to shape the future of healthcare.

Cynata Therapeutics Ltd is primarily present in Australia, where it is headquartered.

Cynata Therapeutics Ltd has achieved several significant milestones. Firstly, the company successfully developed and patented a game-changing Cymerus™ technology, which enables the production of high-quality mesenchymal stem cells. Additionally, they conducted successful preclinical trials, demonstrating the potential of Cymerus™ MSCs in various therapeutic applications. Cynata Therapeutics Ltd also achieved a major milestone by conducting the world's first clinical trial using an allogeneic mesenchymal stem cell product derived from a single induced pluripotent stem cell donor. Furthermore, the company secured collaboration and licensing agreements with renowned pharmaceutical companies, further validating their technology and expanding their reach in the global market.

Cynata Therapeutics Ltd is an Australian-based biotechnology company specializing in regenerative medicine. Established in 2011, the company focuses on developing innovative therapeutic stem cell products for a broad range of medical conditions. With a strong emphasis on clinical advancements, Cynata Therapeutics has made significant progress in stem cell research and development. Boasting a team of accomplished scientists and researchers, the company's revolutionary Cymerus™ platform technology allows for large-scale production of high-quality mesenchymal stem cells. Cynata Therapeutics is committed to transforming healthcare through their groundbreaking stem cell technology, offering hope for the treatment of various diseases and conditions.

The main competitors of Cynata Therapeutics Ltd in the market are Mesoblast Limited, Pluristem Therapeutics Inc., and Athersys Inc.

Cynata Therapeutics Ltd is primarily active in the biotechnology and pharmaceutical industries.

Cynata Therapeutics Ltd is a biotechnology company with a unique business model focused on regenerative medicine. The company specializes in the development and commercialization of a proprietary stem cell technology known as Cymerus™. This technology enables large-scale production of high-quality mesenchymal stem cells (MSCs) from a single donor, eliminating the need for multiple donors. Cynata Therapeutics aims to utilize this technology to address a wide range of therapeutic applications, including graft-versus-host disease, cardiovascular diseases, osteoarthritis, and respiratory disorders. By leveraging their innovative Cymerus™ platform, Cynata Therapeutics strives to revolutionize the way regenerative medicine is approached and provide effective treatments for various medical conditions.

De K/W-verhouding kan momenteel niet worden berekend voor Cynata Therapeutics.

De KUV kan momenteel niet worden berekend voor Cynata Therapeutics.

De AlleAktien Kwaliteitsscore voor Cynata Therapeutics is 5/10.

De omzet kan momenteel niet worden berekend voor Cynata Therapeutics.

De winst kan momenteel niet berekend worden voor Cynata Therapeutics.

Cynata Therapeutics Ltd is an Australian biotechnology company specializing in the development of cellular therapies for the treatment of various diseases. The company's business model is based on the use of its proprietary mesenchymal stem cell technology, which enables a wide range of potential applications. Cynata Therapeutics has divisions focusing on regenerative medicine, specifically therapies for tissue regeneration after injuries or diseases, and immunotherapy, aiming to improve the body's immune system for more effective cancer and disease treatment. The company also offers various products based on its mesenchymal stem cell technology for research and development in cell-based therapies. Cynata Therapeutics operates through innovation, research, and development, continually investing in its scientists and research partners to improve its technology and discover new applications. Additionally, it collaborates with leading researchers and institutions to share findings and promote therapy development. The company also pursues international cooperation and partnerships to market and utilize its technology and products globally, recently partnering with Fujifilm for distribution in Japan and other Asian markets. In summary, Cynata Therapeutics provides a wide range of cellular therapies and products based on its mesenchymal stem cell technology, aiming to improve patient care and offer solutions for serious and life-threatening diseases. With its strong research efforts and international focus, the company will continue to play a leading role in the cellular therapy market and establish itself in the field of regenerative medicine and immunotherapy.

Cynata Therapeutics keert een dividend van 0 AUD uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Cynata Therapeutics of het bedrijf keert geen dividend uit.

De ISIN van Cynata Therapeutics is AU000000CYP7.

Het WKN van Cynata Therapeutics is A1W8VE.

De ticker van Cynata Therapeutics is CYP.AX.

Binnen de laatste 12 maanden betaalde Cynata Therapeutics een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Cynata Therapeutics naar verwachting een dividend van 0 AUD betalen.

De dividendrendement van Cynata Therapeutics is momenteel .

Cynata Therapeutics betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Cynata Therapeutics betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 AUD verwacht. Dit komt overeen met een dividendrendement van 0 %.

Cynata Therapeutics wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Cynata Therapeutics van 1-11-2024 ter hoogte van 0 AUD te ontvangen, moest je het aandeel voor de ex-datum op 1-11-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 1-11-2024.

In het jaar 2023 heeft Cynata Therapeutics 0 AUD aan dividenden uitgekeerd.

De dividenden van Cynata Therapeutics worden in AUD uitgekeerd.